Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The translational roles of circular RNAs in cancers and their underlying molecular mechanisms.

Medical oncology (Northwood, London, England)·2026

Same author

Diverse radical transformations of allenic C(sp)-C(sp<sup>2</sup>) and C(sp<sup>3</sup>)-C(sp<sup>2</sup>) bonds enabled by silyl substitution.

Nature communications·2026

Same author

Serum BP180 and BP230 autoantibodies in Alzheimer's disease: diagnostic and cognitive associations in a retrospective study.

Frontiers in aging neuroscience·2026

Same author

Integrated multi-omics profiling of treatment-naive cervix uteri premalignant lesions and cervical squamous cell carcinoma reveals ecosystem and drivers underlying cervical cancer progression.

Cell death & disease·2026

Same author

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review.

Frontiers in immunology·2026

Same author

Evaluation of the Effectiveness of Longitudinal Incision for Endoscopic Submucosal Excavation of Gastric Subepithelial Lesions.

Journal of visualized experiments : JoVE·2026

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Bergmeyer Glucose Quantification for Microbiological Samples

Bergmeyer Glucose Quantification for Microbiological Samples

Published on: January 17, 2025

pH-insensitive glucose indicators.

Jared R Garrett¹, Xinxin Wu, Sha Jin

¹College of Engineering, University of Arkansas, Fayetteville, AR 72701, USA.

Biotechnology Progress

|February 6, 2009

Summary

This summary is machine-generated.

This study developed a new biosensor for real-time, intracellular glucose monitoring. The engineered glucose indicator protein (GIP) functions reliably even in acidic cellular environments, overcoming previous limitations.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Related Experiment Videos

Last Updated: Jun 25, 2026

Bergmeyer Glucose Quantification for Microbiological Samples

Bergmeyer Glucose Quantification for Microbiological Samples

Published on: January 17, 2025

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Area of Science:

Biotechnology
Molecular Biology
Cellular Physiology

Background:

Real-time, noninvasive intracellular glucose monitoring is crucial for understanding cellular metabolism.
Previous glucose indicator proteins (GIPs) exhibited pH sensitivity, limiting their use in fluctuating intracellular pH environments.
Intracellular pH varies significantly across cellular compartments and metabolic states.

Purpose of the Study:

To engineer a novel GIP with enhanced tolerance to pH changes for accurate intracellular glucose measurement.
To overcome the limitations of pH-sensitive fluorescent proteins in existing GIPs.
To enable reliable glucose monitoring in diverse cellular compartments and conditions.

Main Methods:

Constructed a new GIP by linking a glucose-binding protein with cyan and pH-insensitive yellow fluorescent proteins.
Utilized Förster resonance energy transfer (FRET) for conformational change-induced glucose detection.
Evaluated GIP performance across a range of pH values (7.3 to 5.3).

Main Results:

The newly developed GIP demonstrated significantly improved tolerance to pH variations.
The glucose response of the engineered GIP remained stable from pH 7.3 down to 5.3.
This indicates robust functionality in acidic intracellular environments.

Conclusions:

The pH-tolerant GIP is a promising tool for accurate, real-time intracellular glucose monitoring.
This biosensor overcomes limitations of previous GIPs in acidic cellular conditions.
Enables advanced research into cellular metabolism and disease states.